Literature DB >> 6980076

Dose- and time-related effect of troleandomycin on methylprednisolone elimination.

S J Szefler, M Brenner, W J Jusko, S L Spector, K A Flesher, E F Ellis.   

Abstract

Effects of varying doses of troleandomycin (TAO) on methylprednisolone disposition were examined in five steroid-dependent asthmatic patients. The characteristic reduction in methylprednisolone elimination in the presence of TAO after a 40 mg IV methylprednisolone was also present after methylprednisolone doses as low as 4 mg. In patients receiving continuous TAO on an every-other-day basis, inhibition of methylprednisolone elimination was impaired to a greater extent on the "day on" TAO than on the "day off" TAO Methylprednisolone elimination on the day off TAO was still slower than that before TAO, however, TAO on a multiple-dose schedule resulted in greater reduction of methylprednisolone elimination than after a single TAO dose. These results suggest that TAO induces immediate and continued inhibition of methylprednisolone disposition.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980076     DOI: 10.1038/clpt.1982.143

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Macrolide immunomodulation of chronic respiratory diseases.

Authors:  Daniel P Healy
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

Review 2.  Clinical pharmacology of asthma. Implications for treatment.

Authors:  A J Frew; S T Holgate
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 3.  Corticosteroid sparing agents in asthma.

Authors:  J M Hill; A E Tattersfield
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

4.  Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.

Authors:  B Lebrun-Vignes; V C Archer; B Diquet; J C Levron; O Chosidow; A J Puech; D Warot
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 5.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

Review 7.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

8.  Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.

Authors:  D Warot; L Bergougnan; D Lamiable; I Berlin; G Bensimon; P Danjou; A J Puech
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 10.  Pharmacokinetic interactions of the macrolide antibiotics.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.